Finance

Lists
Q3 2026 earnings • released • EPS miss -8,20%
See results
CTNM:NASDAQ
Contineum Therapeutics Inc
US$9,52
+8,06%
(+0,71) 1D
6 ພ.ຈ., 16 ໂມງ 0 ນາທີ 01 ວິນາທີ GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CTNM...
Open
US$8,96
High
US$9,79
Low
US$8,59
Mkt. cap
373,81 ລ້ານ
Avg. vol.
1,14 ລ້ານ
Volume
343,54 ພັນ
52-wk high
US$17,78
52-wk low
US$6,72
EPS
US$-1,77
Shares outstanding
35,35 ລ້ານ
No. of employees
51
Open
US$8,96
High
US$9,79
Low
US$8,59
Mkt. cap
373,81 ລ້ານ
Avg. vol.
1,14 ລ້ານ
Volume
343,54 ພັນ
52-wk high
US$17,78
52-wk low
US$6,72
EPS
US$-1,77
Shares outstanding
35,35 ລ້ານ
No. of employees
51
News stories
From web sources and news partners
Investing.com Canada
Investing.com Canada
·
3 ມື້ກ່ອນ
Form 8K Contineum Therapeutics Inc For: 3 November By Investing.com
About Contineum Therapeutics Inc
CEO-
Employees51
Founded2009
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websitecontineum-tx.com
Analyst ratings
Based on 8 analysts giving stock ratings to CTNM in the past 3 months
Strong buy
Buy
6
Hold
2
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for CTNM in the last 3 months.
Highest
Current US$9,52
US$30,00 (+215,13%)
Average
US$22,14 (+132,56%)
Lowest
US$14,00 (+47,06%)
Analyst
Recommendation
Action
Price target
Projected
Date
Brian Abrahams
RBC Capital
Buy
Maintained
US$21,00
+120,6%
11/03/2026
Debanjana Chatterjee
JonesTrading
Buy
Reiterated
US$30,00
+215,1%
11/03/2026
Charles Moore
Robert W. Baird
Hold
Downgraded
US$14,00
+47,1%
10/14/2026
Sean Laaman
Morgan Stanley
Hold
Maintained
US$17,00
+78,6%
10/12/2026
Paul Matteis
Stifel Nicolaus
Buy
Reiterated
US$28,00
+194,1%
10/12/2026
Myles Minter
William Blair
Buy
Maintained
-
-
09/30/2026
Gaurav Maini
LifeSci Capital
Buy
Maintained
US$23,00
+141,6%
09/29/2026
Unknown Analyst
Leerink Partners
Buy
Maintained
US$22,00
+131,1%
09/16/2026
Last report
3 ພ.ຈ. 2026
Fiscal period
Q3 2026
US$-0,49 / US$-0,45
-8,20%miss
Revenue / Est. (USD)
- / 0,00
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
ທ.ວ. 2025
ມ.ນ. 2026
ມິ.ຖ. 2026
ກ.ຍ. 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
12,00 ລ້ານ
11,14 ລ້ານ
11,97 ລ້ານ
15,26 ລ້ານ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5,12 ລ້ານ
5,76 ລ້ານ
5,45 ລ້ານ
5,70 ລ້ານ
Operating expense
17,12 ລ້ານ
16,90 ລ້ານ
17,43 ລ້ານ
20,97 ລ້ານ
Total operating expenses
17,12 ລ້ານ
16,90 ລ້ານ
17,43 ລ້ານ
20,97 ລ້ານ
Operating income
-17,12 ລ້ານ
-16,90 ລ້ານ
-17,43 ລ້ານ
-20,97 ລ້ານ
Other non operating income
-51,00 ພັນ
-57,00 ພັນ
-68,00 ພັນ
-93,00 ພັນ
EBT including unusual items
-15,16 ລ້ານ
-14,46 ລ້ານ
-15,15 ລ້ານ
-18,70 ລ້ານ
EBT excluding unusual items
-15,16 ລ້ານ
-14,46 ລ້ານ
-15,15 ລ້ານ
-18,70 ລ້ານ
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-15,16 ລ້ານ
-14,46 ລ້ານ
-15,15 ລ້ານ
-18,70 ລ້ານ
Net profit margin
-
-
-
-
Earnings per share
-0,49
-0,39
-0,40
-0,49
Interest and investment income
2,01 ລ້ານ
2,50 ລ້ານ
2,34 ລ້ານ
2,36 ລ້ານ
Interest expense
-
-
-
-
Net interest expenses
2,01 ລ້ານ
2,50 ລ້ານ
2,34 ລ້ານ
2,36 ລ້ານ
Depreciation and amortization charges
-
-
-
-
EBITDA
-17,03 ລ້ານ
-16,82 ລ້ານ
-17,29 ລ້ານ
-20,88 ລ້ານ
Gain or loss from assets sale
-
2,00 ພັນ
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
ແອັບຂອງ Google